China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
SHENZHEN, CHINA, Aug. 24, 2023 (GLOBE NEWSWIRE) --
- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression.
- The product will enrich the cardio-cerebrovascular (including the central nervous system) pipeline of the Group. After approved for marketing in China, it is expected to meet the clinical needs of drug with both safety and efficacy, providing new treatment options to ischemic stroke patients in China.
On August 24, China Medical System Holdings Limited (“CMS” or the “Group”) announced that the Group entered into a Collaboration Agreement (the “Agreement”) with Nanjing NeuroDawn Pharmaceutical Co. Ltd. (“NeuroDawn Pharmaceutical”), for anti-ischemic stroke brain cytoprotectant and class 1 innovative drug Y-3 injection (“Y-3 injection” or the “Product”), and gained an exclusive promotion right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of the Agreement is permanent.
Y-3 Injection is a Class 1 innovative drug - small molecule compound, which is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The mechanism of action of the Product is to dissociate PSD-95 and nNOS coupling and activate α2-GABAA receptors. With dual-target intervention at the same time and its clear mechanism of action, the Product is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression.
Stroke is a major non-communicable disease that seriously endangers the health of Chinese people. The overall lifetime risk of stroke in China is 39.9%, ranking the first in the world. The number of new cases of ischemic stroke in China was approximately 2.87 million in 2019, and the incidence rate substantially increased by 226.5% from 1990 to 2019, with a large patient population. Stroke has the characteristics of high disability rate and heavy economic burden. There is an urgent clinical need for evidence-based drugs to reduce family and social burdens.
In January 2023, The Phase I clinical trial of the Product in China has been completed and the results showed a good overall safety. The Product is currently in the Phase II clinical trial in China. If approved for marketing in China, it will bring new treatment options to ischemic stroke patients in China, meet the clinical needs of drug with both safety and efficacy, and thus benefit the patients.
CMS has been deeply engaged in the cardio-cerebrovascula/central nervous system therapeutic fields for years and possesses XinHuoSu (recombinant human brain natriuretic peptide for injection), Deanxit (flupentixol and melitracen tablets) and VALTOCO (the first diazepam nasal spray approved in China), etc. The Group has also established a compliant and efficient commercialization system in the cardio-cerebrovascular and central nervous system fields. In the future, the Group will continue to prioritize patients and clinical needs, strategically deploy more differentiated innovative drugs, and consistently expand the product portfolio in the Group's advantageous specialty fields, benefiting a greater number of patients.
For further detailed information, please visit the following link for the, “Voluntary and Business Update Announcement Gaining Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug” issued by CMS on August 24 2023.
About NEURODAWN PHARMACEUTICAL
NeuroDawn Pharmaceutical, based in Nanjing, China, is an innovation and R&D-driven new drug company, focusing on the research and development of new drugs for central nervous system (CNS) diseases. NeuroDawn Pharmaceutical has established a comprehensive internal R&D platform, including chemical synthesis, biological screening, CMC (chemistry, manufacturing and control) development, DMPK (drug metabolism and pharmacokinetics) research, in vivo pharmacology research, toxicology research and clinical research, etc. In addition, NeuroDawn Pharmaceutical has integrated clinical resources for neurological diseases in China and established close collaboration with more than one hundred leading hospitals in China to provide comprehensive and complete technical services and professional guidance for clinical studies.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.
CMS focuses on developing first- or best-in-class innovative products and has made the layout of about 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email:
Website:
Source: China Medical System Holdings Ltd.
